September 21, 2022
Takeda Pharmaceutical said on September 16 that a key European panel recommended approval for maribavir for the treatment of adults with post-transplant cytomegalovirus (CMV) infection refractory to prior therapies. The drug, a CMV-specific UL97 protein kinase inhibitor, gained a positive...read more